414results about "Radioactive preparation forms" patented technology

The present invention discloses a medical microsphere and its preparation method and application. The medical microsphere includes phenolic resin microspheres and radioactive metal elements loaded on the phenolic resin microspheres; the average particle size of the phenolic resin microspheres is 1 to 150 μm. The medical microsphere in the present invention can not only achieve local cell killing in the blood vessels of a specific part, but also effectively avoid the occurrence of fragmentation; further, the medical microsphere has a good loading rate and an extremely low exudation loss rate, which can meet the loading and safety requirements of radioactive elements; in addition, the preparation method of the medical microsphere is simple.

Methods and compositions for inducing long-term tolerance by hybrid nanoparticles are provided. Compositions and formulations comprising hybrid nanoparticles with inherent affinity for innate immune cells are provided.

Disclosed herein are methods and systems for the use of extraction chromatography resins to concentrate Ac from dilute solutions that may contain Th isotopes and / or other isotopes, such as Ra. As disclosed herein, at least some extraction chromatography resins strongly retain trivalent actinides between 4 and 6 M HNO3 that can be recovered in good yields with small volumes of dilute acids. These small volumes of acid eluents result in significant concentration of the solution of the trivalent / certain tetravalent ions, such that they can be further processed without requiring lengthy evaporation steps that are utilized in standard Ac concentration methods.

A method of generating an emulsion for treating a patient. The method includes generating a water-based solution carrying an agent which turns into a hydrogel by addition of calcium ions. Radium radionuclides are added to the water-based solution in a concentration sufficient for radiotherapy. After adding the radium to the water-based solution, the water-based solution is mixed with an emulsifier and an oil.

The present invention relates to an isolated cellular targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and / or a label as well as methods for producing such isolated cellular targeted delivery system and uses of such system for therapy diagnosis and in particular for diagnosis of cancer, particularly metastatic cancer, in particular for therapy of cancer.

The present disclosure relates to enriched and stable radiopharmaceutical compositions comprising [225Ac]Ac-DOTA-TATE.

The present disclosure relates to stable compositions comprising a radiolabeled compound, and related pharmaceutical compositions and methods of manufacture. Such compositions are useful in both the diagnostic imaging of and the treatment of diseases (e.g., cancer).

Systems and methods are disclosed for determining the spatial distributions of radionuclides in tissue samples via mass spectrometry imaging. After administration of a radiopharmaceutical that contains a radionuclide, a mass spectrometry imaging system, such as an imaging mass cytometer or a multiplexed ion beam imaging system, is employed to interrogate a tissue sample to obtain a dataset. The radiopharmaceutical includes, or generates via radioactive decay of the radionuclide, a metal isotope detectable by the mass spectrometry imaging system. The dataset is processed to determine a spatial distribution of the metal isotope within the tissue sample, thereby characterizing the spatial distribution of the radionuclide delivered within the tissue sample. The tissue sample may be stained with a biomarker reagent that includes an additional metal isotope attached to a biomarker ligand, enabling the spatially multiplexed and co-registered analysis. The present methods can be adapted to infer and assess localization of non-radioactive pharmaceuticals.

The present disclosure relates to pharmaceutical compositions comprising [61Cu]Cu-NODAGA-LM3 or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of imaging subjects suspected of having or diagnosed with a somatostatin receptor subtype 2 (SST2)-expressing tumor by administering the pharmaceutical compositions described herein and generating one or more radiographic images of the subject.

The present disclosure generally relates to materials, processes, generators, and / or systems, for generating radioisotope. The present disclosure also generally relates to ceramic materials comprising radioisotope suitable for use in a radioisotope generator. The present disclosure also generally relates to processes, generators and / or systems, for producing and capturing radioisotope. The present disclosure also generally relates to the preparation of radioisotope solutions for use in radiopharmacy and / or other clinical applications.

The application provides a radionuclide nanohydrogel microneedle and a preparation method and application thereof, and belongs to the field of nanobiomedicine. 32 P-labeled calcium phosphate, which is formed by a biomimetic reaction of Ag2S@Ca 32 P nanoparticles, and a base layer which is a base matrix and comprises hyaluronic acid 32 P nanohydrogel microneedle can release Ag2S nanoparticles in response to a weakly acidic tumor environment, and under the irradiation of near-infrared light, the photothermal conversion efficiency can effectively kill bacteria, effectively improve the tumor hypoxic environment, enhance the treatment effect of radionuclides, play an antibacterial and wound healing promoting role in melanoma defect repair, and maximize the inhibition of tumor growth and tumor recurrence.

The present invention relates to MOFs for radiotherapy. More specifically, the present invention provides: a particle comprising an MOF, optionally at least one targeting moiety, and at least one beta-emitting radionuclide; a composition comprising the particles; said particles or composition for use as a medicament; said particles or compositions for use in a method of treating a proliferative disease; and a kit comprising a particle comprising an MOF, optionally a targeting moiety, and a beta-emitting radionuclide.

Liposomes encapsulating a radioisotope can be used in the treatment of cancers including, but not limited to, leptomeningeal metastases. In an embodiment, liposome encapsulating a radioisotope comprising (186Re) obisbemeda can be administered to a patient through an Ommaya reservoir. The therapies can include imaging the liposome encapsulating a radioisotopе concomitant or subsequent to administration. Longitudinal analysis of the presence of tumor cells and biomarkers can be used to inform treatment strategy.

The present disclosure generally relates to materials, processes, generators, and / or systems, for generating radioisotope. The present disclosure also generally relates to ceramic materials comprising radioisotope suitable for use in a radioisotope generator. The present disclosure also generally relates to processes, generators and / or systems, for producing and capturing radioisotope. The present disclosure also generally relates to the preparation of radioisotope solutions for use in radiopharmacy and / or other clinical applications.

The invention relates to a 14C urea pharmaceutical composition for helicobacter pylori diagnosis and application of the 14C urea pharmaceutical composition. The 14C urea pharmaceutical composition comprises 14C urea, 12C urea, citric acid, malic acid and mannitol. According to the invention, the 12C urea and the 14C urea are added together, so that the radioactivity can be ensured, the stability of the medicine can be improved, and the auto-radiolysis of 14C can be reduced. Besides, citric acid, malic acid and mannitol have a remarkable synergistic effect in the aspect of improving the radioactive activity and radiochemical purity of the composition, the stability of the 14C urea pharmaceutical composition can be improved, meanwhile, the activity of urease generated by helicobacter pylori can be improved, and the detection sensitivity and detection efficiency are further guaranteed.

The invention discloses a radioactive medical isotope Ra-223 stably-labeled rare earth nano diagnosis and treatment preparation as well as a preparation method and application thereof. According to the invention, by constructing a dual protection mechanism of the shell layer and the functional biomolecular layer, the Ra-223 is effectively packaged, the recoil nuclei of the Ra-223 are reserved at the tumor part and are prevented from escaping to the surrounding environment of the tumor, the safety of the Ra-223 treatment process can be enhanced, the radioactive energy is ensured to accurately act on the focus, and the treatment effect of the Ra-223 is improved. Meanwhile, the damage risk to healthy tissues is minimized.

The present invention belongs to the field of biomedicine and provides radioactive silica microspheres coated with biomedical polymer materials, as well as a preparation method and application thereof. The method comprises the following steps: S1, mixing silica microspheres, water, and a radioactive nuclide to obtain a radioactive silica microsphere mixture; S2, mixing the radioactive silica microsphere mixture with an alkaline solution and reacting to obtain radioactive silica microspheres; S3, mixing the radioactive silica microspheres with a biomedical polymer solution and coating the mixture to obtain radioactive silica microspheres coated with biomedical polymer materials. The preparation method provided by the present invention is simple, and the prepared radioactive silica microspheres coated with biomedical polymer materials have a high radionuclide labeling rate, a low escape rate, good radiostability, and excellent biosafety, and can be used for the embolization treatment of all solid tumors.

The present application provides a liquid composition of Compound I, a preparation method therefor, and an application thereof, wherein same is selected from one or more among vitamin C, sodium vitamin C, and gentisic acid. By optimizing process parameters and technological process, the method of the present application can be applied to large-scale production, and the product prepared has high radiochemical purity, high activity and concentration, good product stability, high and stable yield or productivity.

The invention discloses a coated yttria-90 loaded radioactive microsphere and a preparation method and application thereof, and relates to the technical field of radioactive microsphere preparation, and the preparation method comprises the following steps: preparing a polyvinyl alcohol microsphere by using a microfluidic technology; the preparation method comprises the following steps: labeling polyvinyl alcohol microspheres with yttrium-90 radionuclide to obtain yttrium-90 loaded radiation microspheres; and coating the polylactic acid-glycolic acid copolymer on the surface of the yttria-90 loaded radioactive microsphere to obtain the coated yttria-90 loaded radioactive microsphere. The composite radioactive microspheres with uniform particle size, stable radioactivity and controllable characteristics can be obtained, and the composite radioactive microspheres are expected to be applied to transcatheter arterial radioembolism (TARE) treatment of liver cancer.

This invention discloses a lipid assembly loaded with 5-aminolevulinic acid and its preparation method. The lipid assembly is a hollow sphere with a core consisting of a hydrophilic phospholipid-chelating agent conjugate formed by chelation with a reactive phospholipid PEG reagent. The outer layer of the phospholipid-chelating agent conjugate is loaded with 5-aminolevulinic acid via hydrazone bonds, and then combined with a radionuclide as an internal light source excitation photosensitizer. The lipid assembly is loaded with 5-ALA via hydrazone bonds. Utilizing the acid-sensitive bond-breaking characteristics of hydrazone bonds and the prodrug properties of 5-ALA, combined with a radionuclide labeled on the surface of the lipid assembly as an internal light source excitation photosensitizer, this invention can overcome the limitations of external light penetration depth in traditional photodynamic therapy, achieving deep PDT treatment. Combined with chemotherapy drugs, it can minimize the toxic side effects on normal tissues during the combined use of radionuclides and photosensitizers in targeted therapy.

The present invention discloses a device for manufacturing developing microspheres and a method for manufacturing developing microspheres, wherein the device for manufacturing developing microspheres is used to manufacture developing microspheres, aiming to solve the problems of inconsistent microsphere size, low production efficiency and complex operation in the prior art. The device comprises a rotatable inner cylinder and a stationary outer cylinder. A microsphere precursor solution is introduced into the space between the inner cylinder and the outer cylinder as a dispersed phase through a syringe. The space has a continuous phase and forms uniform microspheres under the shear force of the inner cylinder, which are finally collected in a collection tray. By precisely controlling the rotation speed of the motor, the aperture of the injection needle of the syringe and the flow rate of the precursor solution, the present invention can manufacture developing microspheres with uniform size and low polydispersity. In addition, the design of the developing microsphere manufacturing device also takes fluid stability into consideration. By adding a rod in the collection tray and arranging a bearing at the bottom of the inner cylinder, the bearing and the rod cooperate to reduce the swing and turbulence of the inner cylinder, thereby further improving the production quality of the developing microspheres.

The application provides probiotic oral burst balls and a preparation process, and belongs to the technical field of probiotic embedding. The probiotic oral burst balls comprise core materials and wall materials. The core materials comprise probiotic raw materials, a flavoring agent, mannose, xylitol, mannose oligosaccharide, glycine, vitamin E and a solvent 1, and the solvent 1 is an oily solvent. The wall materials comprise trehalose, gelatin, cyclic dextrin and a solvent 2, and the solvent 2 is an oily solvent. The probiotic oral burst balls prepared by the preparation process have the characteristics of temperature resistance, acid resistance and storage resistance.

The present disclosure generally relates to materials, processes, generators, and / or systems, for generating radioisotope. The present disclosure also generally relates to ceramic materials comprising radioisotope suitable for use in a radioisotope generator. The present disclosure also generally relates to processes, generators and / or systems, for producing and capturing radioisotope. The present disclosure also generally relates to the preparation of radioisotope solutions for use in radiopharmacy and / or other clinical applications.

A method for producing a titanium molybdate material.SOLUTION: The method includes reacting a metallic molybdenum-99 (Mo-99) material in a liquid medium with a first acid to obtain a Mo composition, combining the Mo composition with a titanium source to obtain a Ti-Mo composition, and pH adjusting the Ti-Mo composition with a base to precipitate a plurality of Ti-Mo particulates.SELECTED DRAWING: Figure 1

An aqueous emulsion system substantially or completely devoid of an oil phase. The aqueous emulsion can be used as a platform to solubilize poorly water-soluble chemical compounds for use in a variety of fields, including the pharmaceutical, cosmetic, skin care, personal care, food, and industrial arenas. The aqueous emulsion can be delivered to a human or animal via a variety of modes to treat a diverse number of ailments, such as a topical composition to promote hair growth or treat skin disorders. Stable and transparent formulations of the aqueous nano-emulsions described herein can be used to treat and / or prevent hair loss, to treat warts and cold sores, or to treat varicose veins.

A method for preparing a radioactive yttrium salt particle suspension comprising multiple steps, including using a hydrothermal process in which a solution of soluble yttrium salts from the group of yttrium chloride, yttrium nitrate, yttrium sulfate, and yttrium bromide is mixed with a stoichiometric excess of phosphate and a solution of sodium phosphate, which when mixed have a suitable pH.

The present invention provides a pharmaceutical composition comprising a radiolabeled complex comprising a radionuclide and a targeting moiety linked to a chelating moiety, and a stabilizer against radiolytic degradation of a radiolabeled complex comprising para-aminohippuric acid or a pharmaceutically acceptable salt or carboxylic derivative thereof. The pharmaceutical composition of the present invention is characterized by high stability of its radiolabeled complex against radiolytic degradation. The present invention also provides a method for preparing such a pharmaceutical composition, and use of para-aminohippuric acid or a pharmaceutically acceptable salt or carboxylic derivative thereof for the stabilization of the radiolabeled complex of such a pharmaceutical composition.

This invention relates to the fields of brachytherapy and radiosensitization, specifically providing a... 125 I-nano implantable particles, their preparation methods, and applications. 125 The 1-nanometer implanted particles have a core-shell structure, consisting of a particle core and particles adsorbed on the outer surface of the particle core. 125 I and the particles encapsulated in the nucleus and 125 The outer shell of the I-type photosensitizer is a covalent organic framework. This invention... 125 The core of the I-nanometer implanted particle is used to enhance the energy deposition of gamma rays and X-rays, generating more hydroxyl radicals; the shell containing a type I photosensitizer is used to absorb the energy of Auger electrons and internal conversion electrons and excite the photosensitizer to generate singlet oxygen, effectively improving the response to... 125 The efficiency of I decay energy utilization. 125 I-nano implanted particles, combined with internal radiation therapy and radiodynamic therapy, destroy tumor cell DNA and cell membranes, enhance tumor killing and induce immunogenic cell death, thereby activating anti-tumor immunity and inducing remote effects.